ifosfamide + doxorubicin + carboplatin

ifosfamide + doxorubicin + carboplatin is a combination chemotherapy regimen consisting of an alkylating agent, an anthracycline, and a platinum-based antineoplastic. Ifosfamide is a nitrogen mustard derivative that acts by cross-linking DNA strands; doxorubicin is an anthracycline that intercalates into DNA and inhibits the enzyme topoisomerase II; and carboplatin is a platinum agent that forms reactive complexes causing intra- and inter-strand DNA cross-links. While this specific combination is more commonly associated with the treatment of solid tumors (such as sarcomas) and certain lymphomas, it is listed here in the context of a Phase 3 trial for acute myeloid leukemia (AML) at The First Affiliated Hospital of Soochow University. However, clinical trial documentation (NCT06043570) for this sponsor and indication defines the 'IAC' regimen as a combination of cladribine, cytarabine (Ara-C), and idarubicin. Therefore, the name 'ifosfamide + doxorubicin + carboplatin' appears to be a mis-expansion of the IAC acronym in this specific therapeutic context.